Evaluation of chelating agents for radioimmunotherapy with scandium-47
- Brookhaven National Laboratory, Upton, NY (United States); and others
Sc-47 has attractive properties [t{1/2} 3.35d, {beta}{sub max}:441 keV (68%), 601 keV (32%); {gamma} 159.4 keV (68%)] for radioimmunotherapy. Sc also displays favorable coordination chemistry for chelation attachment to antibodies. Due to chemical similarities to In and Y we have tested ligands with Sc-47 originally developed for use with In-111 or Y-90. The Scl-47 was produced with a fast neutron reaction Ti-47 (n,p). The radiochemical separation used cation exchange (AG-MP50) loaded with a 2% H{sub 2}O{sub 2} - 1 M H{sub 2}SO{sub 4} solution, followed by elution of Sc-47 with a 1 M NH{sub 4}{sub 2}SO{sub 4}/0.25 M H{sub 2}SO{sub 4} solution. Further separation and conversion of Sc to chloride form is achieved with a Chelex 100 column. No traces of Ti or Fe could be detected by spectrophotometric assay. Anti-CEA F(ab{prime});{sub 2} antibody conjugates of the following chelates were used for labeling studies: 4-isothiocyanato-cyclohexyl EDTA (4-ICE), N-hydroxysuccinimide ester of DOTA {l_angle}DOTA NHS{r_angle}, 2-{l_angle}p-SCN-Bz{r_angle}-6 methyl DTPA {l_angle}1B4MDTPA{r_angle} and conventional DTPA dianhydride. Labeling yields with Sc-47 were, 4-ICE 80%, DOTAQ-NHS 64%, 1B4MDTPA 98% and DTPA 62%. Serum stability of these preparations was essentially 100% out to 48 h except for DTPA (61%). The biodistribution {l_angle}% ID/g{r_angle} of these conjugates in human tumor xenografted nude mice {l_angle}LS-174% cells{r_angle} was compared. 4-ICE, DOTA-NHS and 1B4M-DTPA(15.4, 7.0, 7.0) but liver uptake was somewhat higher for DOTA-NHS than 4-ICE or 1B4M-DTPA (9.4, 5.8, 5.6). Generally faster whole body clearance for 1B4M-DTPA led to somewhat better tumor to organ ratios by 48 h. The poor stability of DTPA conjugate was evident with poor tumor uptake (12.4), high kidney (14.8), liver (17.1) and bone (3.6). We conclude that ligands which perform better with In-111 and Y-90 also give stable Sc-47 conjugates and their biodistributions are favorable for radioimmunotherapy.
- Research Organization:
- Brookhaven National Laboratory (BNL), Upton, NY
- DOE Contract Number:
- AC02-76CH00016
- OSTI ID:
- 441611
- Report Number(s):
- CONF-950603--
- Journal Information:
- Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: Suppl.5 Vol. 36; ISSN 0161-5505; ISSN JNMEAQ
- Country of Publication:
- United States
- Language:
- English
Similar Records
Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72. 3 in athymic mice bearing human colon carcinoma xenografts
Improved production, and evaluation of Cu-67 for tumor radioimmunotherapy